Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma)

重组抗HER2人源化单克隆抗体-MCC-DM1偶联剂（上海医药集团）

Report date: 2025/03/07 17:33:34

Base Information

Drug NameAnti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma)
Drug Alias NameTrastuzumab emtansine biosimilar (Shanghai Pharma)注射用重组抗HER2人源化单克隆抗体-MCC-DM1偶联剂恩美曲妥珠单抗生物类似药（上海医药）B-003 (Shanghai Pharma)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MCC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionTubulin inhibitorsAnti-HER2
TargetsTubulinReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Crosslink Pharmaceutical R & D Co LtdShanghai Pharmaceuticals Holding Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Pharmaceuticals Holding Co LtdShanghai Crosslink Pharmaceutical R & D Co Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A